CD274 and gastric adenocarcinoma: In a pilot phase 1b study, KEYNOTE-012, pembrolizumab was first tested in patients with PD-L1-positive recurrent or metastatic gastroesophageal junction (GEJ) and gastric adenocarcinoma, without limitation on the number of lines of previous therapy (Muro et al., 2016).